| About the editor and disclosure of conflicts of interest |
|
xv | |
| About the authors and disclosure of conflicts of interest |
|
xvii | |
| Foreword |
|
xxiii | |
| Acknowledgments |
|
xxv | |
| Executive summary |
|
xxix | |
| Introduction |
|
xxxix | |
| Nine future thoughts for the day after tomorrow |
|
xlvii | |
|
PART 1 WHY: GLOBAL HEALTHCARE SYSTEMS UNDER PRESSURE |
|
|
|
Chapter 1 Oxygen required |
|
|
3 | (6) |
|
|
|
|
|
4 | (1) |
|
Patients Are in General Positive, But Expect Better |
|
|
5 | (1) |
|
System Change Required to Create Future Oxygen |
|
|
5 | (1) |
|
The Benefits and Budgets of Drugs in Healthcare Systems |
|
|
6 | (3) |
|
Value for Medication Money |
|
|
7 | (2) |
|
Chapter 2 Innovation biotopes required |
|
|
9 | (12) |
|
|
|
|
|
10 | (2) |
|
General Principles of Successful Innovation |
|
|
12 | (2) |
|
|
|
14 | (1) |
|
|
|
15 | (1) |
|
|
|
16 | (1) |
|
Creating the Best Environment for Combinatoric Innovation |
|
|
17 | (1) |
|
|
|
17 | (1) |
|
|
|
18 | (2) |
|
Ideas Ready to Survive in a Complex World |
|
|
20 | (1) |
|
Chapter 3 Value-based healthcare forestry |
|
|
21 | (6) |
|
|
|
|
|
22 | (2) |
|
Triple Aim and Proving Value of Medicine |
|
|
23 | (1) |
|
The Quantified Self to Measure Outcomes |
|
|
24 | (1) |
|
Driving Value as a Pharmaceutical Care Provider |
|
|
25 | (2) |
|
Chapter 4 Hunting grounds of outcome-based financing |
|
|
27 | (8) |
|
|
|
From Activity-Based to Outcome-Based Financing |
|
|
28 | (3) |
|
Changing Models for Spending Control on Drugs |
|
|
29 | (2) |
|
|
|
31 | (1) |
|
Broader Societal Benefits and Health Impact Bonds |
|
|
32 | (1) |
|
Pharmaceutical Care Providers as Drug Outcome Optimizers |
|
|
32 | (3) |
|
Chapter 5 #PatientsIncluded™ botany |
|
|
35 | (12) |
|
|
|
|
|
35 | (1) |
|
Why Healthcare Systems Promote Active Patient Participation |
|
|
36 | (1) |
|
Consumerism to Take Autonomy for Own Healthcare |
|
|
36 | (3) |
|
Targeted Information Supply at Individual Literacy Levels |
|
|
37 | (1) |
|
Care Systems from Volume to Value |
|
|
38 | (1) |
|
Regulatory Interest in Patient Perspectives |
|
|
38 | (1) |
|
What Do Patients Consider as Good Healthcare? |
|
|
39 | (1) |
|
|
|
40 | (4) |
|
Patients Getting Acquainted with Digital Health Technology |
|
|
42 | (1) |
|
Some Examples Where Patients are Making a (Digital) Difference |
|
|
43 | (1) |
|
What Patients Can Expect from Pharmaceutical Care |
|
|
44 | (3) |
|
Not Just a Shop or Department |
|
|
45 | (2) |
|
Chapter 6 Scenery of pharmaceutical care |
|
|
47 | (20) |
|
|
|
|
|
47 | (6) |
|
Digital Pharmaceutical Care |
|
|
49 | (1) |
|
Five Essential Domains of Pharmaceutical Care: The Role of Pharmacists |
|
|
50 | (3) |
|
From Hospital or Community to Home Pharmaceutical Care |
|
|
53 | (1) |
|
|
|
53 | (1) |
|
Preventing Inadequate Drug Use |
|
|
54 | (2) |
|
Avoidable Harm Due to Medication |
|
|
55 | (1) |
|
|
|
55 | (1) |
|
Adherence, Its Relevance and Taxonomy |
|
|
56 | (4) |
|
|
|
58 | (2) |
|
Technology to Support Adherence |
|
|
60 | (1) |
|
Individualized Goal Setting |
|
|
61 | (1) |
|
Return of Investment of an Adherence Program |
|
|
62 | (5) |
|
PART 2 WHAT: DIGITAL ADVANCES TO INNOVATE PHARMACEUTICAL CARE JOURNEYS |
|
|
|
Chapter 7 Abiotic digital health technologies |
|
|
67 | (16) |
|
|
|
|
|
68 | (1) |
|
Booming Digital Health Environment |
|
|
69 | (3) |
|
Digital Health Classification by Type of Data Transfer |
|
|
70 | (1) |
|
WHO Classification of Digital Health Interventions |
|
|
70 | (1) |
|
Health Technology at Different Stages of the Patient Pathway |
|
|
71 | (1) |
|
|
|
72 | (4) |
|
The Promise of Smartphones |
|
|
73 | (1) |
|
Challenges of Health Technology Adoption |
|
|
74 | (2) |
|
Persuasive Health Technology to Drive Adoption |
|
|
76 | (4) |
|
Creating Hooks to Improve Adequate Use of Drugs |
|
|
78 | (1) |
|
Serious Gaming to Change Habits |
|
|
79 | (1) |
|
Economic Benefits of Digital Health |
|
|
80 | (3) |
|
Research on Digital Health Cost-Effectiveness |
|
|
80 | (3) |
|
Chapter 8 Data outback of an internet of (pharma) things |
|
|
83 | (12) |
|
|
|
|
|
84 | (1) |
|
|
|
84 | (2) |
|
Internet of Pharma Things |
|
|
86 | (1) |
|
Data in the Internet of Things |
|
|
87 | (8) |
|
Data in the Health Ecosystem |
|
|
88 | (1) |
|
HL7-FHIR and the Interoperability of Healthcare Applications |
|
|
89 | (1) |
|
|
|
90 | (1) |
|
Turning Health Data Into Knowledge |
|
|
91 | (1) |
|
Considerations for Future IoT Uptake |
|
|
92 | (1) |
|
|
|
93 | (2) |
|
Chapter 9 The jungle of health apps |
|
|
95 | (12) |
|
|
|
|
|
95 | (1) |
|
Categories of Health Apps |
|
|
96 | (1) |
|
Impact on Core Responsibilities in Pharmaceutical Care |
|
|
96 | (1) |
|
Implementation in Daily Practice |
|
|
97 | (3) |
|
For Professional Support: Medical and Pharmaceutical Reference Apps |
|
|
97 | (1) |
|
Logistic Prescription Management Support Apps for Providers and Patients |
|
|
98 | (1) |
|
|
|
98 | (1) |
|
A Wealth of Adherence Improvement Apps |
|
|
99 | (1) |
|
|
|
100 | (7) |
|
Responsibility for Connecting and Working With Health Apps |
|
|
101 | (1) |
|
Simplification Efforts Ongoing |
|
|
101 | (1) |
|
Assessing the Quality of a Health App |
|
|
102 | (1) |
|
Certification of Healthcare Apps |
|
|
103 | (1) |
|
Are Apps as Effective as They Promise? |
|
|
104 | (1) |
|
|
|
105 | (2) |
|
Chapter 10 Rainforests of wearables and insideables |
|
|
107 | (12) |
|
|
|
|
|
107 | (4) |
|
Insideables and Digestables |
|
|
109 | (1) |
|
Virtual Personal Assistants and Wearables |
|
|
110 | (1) |
|
Impact on Core Responsibilities in Pharmaceutical Care |
|
|
111 | (1) |
|
Implementation in Daily Practice |
|
|
111 | (2) |
|
Pharmaceutical Care Providers as Consultants on Use of Health Wearables |
|
|
112 | (1) |
|
Wearables That Empower Pharmaceutical Care Providers' Work |
|
|
113 | (1) |
|
|
|
113 | (6) |
|
Retentive Wearables Use: Bring Your Own health Device |
|
|
113 | (2) |
|
Is a Wearable the Best Solution? |
|
|
115 | (1) |
|
Digital Health Compliance of Wearables |
|
|
115 | (1) |
|
Reliability of Digital Biomarker Data |
|
|
116 | (1) |
|
Resistance to Using Wearables or Insideables |
|
|
116 | (3) |
|
Chapter 11 Sequoias of artificial intelligence |
|
|
119 | (16) |
|
|
|
|
|
120 | (3) |
|
The Promise of Machine Learning |
|
|
121 | (1) |
|
Stream-Mining in Continuous Data Flows |
|
|
122 | (1) |
|
AI Technology in Our Current Era |
|
|
123 | (1) |
|
Impact on Core Responsibilities in Pharmaceutical Care |
|
|
123 | (1) |
|
Implementation in Daily Practice |
|
|
124 | (6) |
|
Examples of ALs Impact on Doctors' Activities |
|
|
125 | (1) |
|
|
|
126 | (1) |
|
|
|
126 | (1) |
|
|
|
127 | (1) |
|
AI to Fuel `"Pharmacy-as-a-Service" Platforms |
|
|
127 | (1) |
|
How to Start Tomorrow With AI? |
|
|
128 | (1) |
|
Kaggle to Answer Pharmaceutical AI Questions |
|
|
129 | (1) |
|
|
|
130 | (5) |
|
Bias and Responsible Data Science |
|
|
130 | (1) |
|
Lack of Differentiation in AI Providers |
|
|
130 | (1) |
|
Proven, Less Complex Machine-Learning Capabilities Can Address Many End-User Needs |
|
|
131 | (1) |
|
|
|
131 | (1) |
|
Competencies and Skills to Evaluate, Build, and Deploy AI Solutions |
|
|
132 | (1) |
|
Privacy, Quality, and Security |
|
|
133 | (2) |
|
Chapter 12 Pharmbot canopies |
|
|
135 | (12) |
|
|
|
|
|
135 | (3) |
|
|
|
135 | (1) |
|
|
|
136 | (1) |
|
Chatbots in Healthcare and Phannbots |
|
|
137 | (1) |
|
Avatars and Digital Humans |
|
|
138 | (1) |
|
Impact on Core Responsibilities in Pharmaceutical Care |
|
|
138 | (1) |
|
Implementation in Daily Practice |
|
|
139 | (4) |
|
Logistic and Administrative Pharmacy Support |
|
|
139 | (1) |
|
Alexa, Can You Help Me With My Medication? |
|
|
140 | (1) |
|
Intelligent Chatbots to Support Triage, Diagnosis, and Screening |
|
|
141 | (1) |
|
|
|
142 | (1) |
|
Closed Loop Medical Ecosystems Required |
|
|
142 | (1) |
|
|
|
143 | (1) |
|
|
|
143 | (4) |
|
Security, Privacy, and Ethics |
|
|
144 | (1) |
|
SPoTs to Facilitate Phannbots |
|
|
144 | (1) |
|
|
|
145 | (2) |
|
Chapter 13 Savanna of virtual, augmented, and mixed reality |
|
|
147 | (10) |
|
|
|
|
|
147 | (2) |
|
Impact on Core Responsibilities in Pharmaceutical Care |
|
|
149 | (1) |
|
Implementation in Daily Practice |
|
|
149 | (4) |
|
VR-AR-MR as a Treatment Option |
|
|
150 | (1) |
|
Interactive Learning and Pharmaceutical Care Support |
|
|
151 | (2) |
|
|
|
153 | (1) |
|
Dynamic Education for Pharmaceutical Care Providers |
|
|
153 | (1) |
|
Supporting the Work-Around in the Community and Hospital Pharmacy |
|
|
153 | (1) |
|
|
|
153 | (4) |
|
|
|
154 | (1) |
|
Potential Adverse Health Effects of VR-AR-MR |
|
|
154 | (1) |
|
Other Challenges to Solve |
|
|
155 | (2) |
|
Chapter 14 Blockchain taiga |
|
|
157 | (12) |
|
|
|
|
|
157 | (3) |
|
Decentralization Can Facilitate Security |
|
|
158 | (1) |
|
|
|
159 | (1) |
|
Impact on Core Responsibilities in Pharmaceutical Care |
|
|
160 | (1) |
|
Implementation in Daily Practice |
|
|
160 | (4) |
|
|
|
161 | (1) |
|
Benefits of Blockchain in Healthcare |
|
|
161 | (1) |
|
Blockchain in Different Pharma Domains |
|
|
162 | (2) |
|
|
|
164 | (5) |
|
If 90% of Functionality is Database-Like: No Blockchain |
|
|
164 | (1) |
|
Speed and Capacity of Blockchain Networks |
|
|
164 | (1) |
|
The Challenge of Identity and Privacy |
|
|
165 | (1) |
|
Uncertainty in Regulation |
|
|
166 | (1) |
|
Development Stage Technical Standards |
|
|
166 | (1) |
|
Making Changes in Blockchain Transactions |
|
|
166 | (3) |
|
Chapter 15 Digital therapeutic mangroves |
|
|
169 | (12) |
|
|
|
|
|
170 | (1) |
|
Impact on Core Responsibilities in Pharmaceutical Care |
|
|
171 | (1) |
|
Implementation in Daily Practice |
|
|
171 | (4) |
|
Digital Therapeutics to Enhance or Replace Medication |
|
|
171 | (1) |
|
The Role of the Pharmacist in a Digital Health Management Team |
|
|
172 | (1) |
|
|
|
173 | (1) |
|
|
|
174 | (1) |
|
Pain, Stress, and Mental Disease Management |
|
|
175 | (1) |
|
|
|
175 | (1) |
|
|
|
175 | (6) |
|
|
|
176 | (1) |
|
Regulatory and Reimbursement Framework |
|
|
177 | (1) |
|
Owner of the Prescription of Digital Therapeutics |
|
|
178 | (3) |
|
Chapter 16 Digital vegetation beyond 2024 |
|
|
181 | (14) |
|
|
|
|
|
181 | (2) |
|
|
|
182 | (1) |
|
|
|
183 | (3) |
|
3D Printing Towards Individualized Dosing |
|
|
183 | (1) |
|
Added Value of 3D Printing |
|
|
184 | (1) |
|
|
|
185 | (1) |
|
|
|
185 | (1) |
|
Social Robots in Every Home |
|
|
186 | (9) |
|
|
|
186 | (1) |
|
Social Companion Robots in Healthcare |
|
|
187 | (1) |
|
Social Robots in Pharmaceutical Care |
|
|
188 | (1) |
|
|
|
189 | (1) |
|
Ethics in the Time of Robotics |
|
|
189 | (1) |
|
|
|
190 | (5) |
|
PART 3 HOW: CONDITIONS TO DRIVE COMBINATORIC PHARMA-DIGITAL INNOVATION |
|
|
|
Chapter 17 Heathlands of digital health compliance |
|
|
195 | (16) |
|
|
|
|
|
|
|
196 | (9) |
|
Compliance Blueprint: What to Do Tomorrow |
|
|
205 | (3) |
|
Compliance Within the Context of Your Organization |
|
|
207 | (1) |
|
Defining Your Compliance Approach |
|
|
208 | (3) |
|
Reduce Compliance Costs and Work |
|
|
208 | (1) |
|
|
|
209 | (2) |
|
Chapter 18 Ethical practice: Fostering trees of life |
|
|
211 | (16) |
|
|
|
|
|
Ethical Practices in a Technological Culture |
|
|
211 | (2) |
|
The Core Values and Virtue-Based Practice of Pharmaceutical Care Providers |
|
|
213 | (2) |
|
|
|
215 | (1) |
|
Technology Versus Humanity |
|
|
216 | (2) |
|
A Principle-Based Approach Is Not Sufficient to Safeguard Holistic Ethical Decision Making |
|
|
217 | (1) |
|
Responsible Research and Use of Technology |
|
|
218 | (3) |
|
|
|
218 | (2) |
|
Responsible Scientific Research |
|
|
220 | (1) |
|
A Meaningful Life and Human Rights in the Digital Age |
|
|
221 | (2) |
|
|
|
222 | (1) |
|
Human Flourishing in a Digital Age |
|
|
223 | (1) |
|
Final Thoughts for Ethically Sound Digital Pharmaceutical Care |
|
|
223 | (4) |
|
|
|
224 | (3) |
|
Chapter 19 Educational biome |
|
|
227 | (16) |
|
|
|
Characteristics of a Professional Practice |
|
|
227 | (1) |
|
Knowledge Domains in Pharmaceutical Care |
|
|
228 | (1) |
|
|
|
228 | (1) |
|
|
|
229 | (1) |
|
Shift From Product-Orientation to Patient-Centricity |
|
|
230 | (1) |
|
Lifelong Learning Paradigm and Adopting Digital Change |
|
|
231 | (1) |
|
A New Fundamental Competency Proposed |
|
|
232 | (3) |
|
Understanding the Ecosystem of Digital Health Technology |
|
|
232 | (1) |
|
|
|
233 | (1) |
|
Specializing in Pharmacy Informatics |
|
|
234 | (1) |
|
General Skills Required for Pharmaceutical Care in the Digital Revolution |
|
|
235 | (2) |
|
Serious Gaming to Enhance Skillsets |
|
|
237 | (1) |
|
The Future of the Pharmaceutical Care Job |
|
|
237 | (6) |
|
Analyze Which Tasks Can Be Automated, and Which Tasks Cannot |
|
|
238 | (1) |
|
Be Prepared for New Roles |
|
|
239 | (4) |
|
PART 4 HOW: WHAT TO DO TOMORROW AS A PHARMACEUTICAL CARE LEADER |
|
|
|
Chapter 20 Digital by Design: Creating effective future oxygen Supply |
|
|
243 | (10) |
|
|
|
Why: Identity True Pharmaceutical Care Problem and the Blue Sky |
|
|
244 | (1) |
|
Who: Select the Most Relevant Patient Group |
|
|
245 | (1) |
|
What: Validate How the Target Population Sees the Blue Sky |
|
|
246 | (1) |
|
How: Choose the Most Suitable Future Solution |
|
|
247 | (2) |
|
Do: Lead the (Digital) Transformation Process |
|
|
249 | (1) |
|
How to Lead Digital Transformation |
|
|
249 | (1) |
|
Sustain: Check the New Process and Adjust Where Required |
|
|
250 | (1) |
|
|
|
251 | (2) |
|
Chapter 21 Hayfields of high-performance cultural transformation |
|
|
253 | (6) |
|
|
|
Why Culture Drives Results |
|
|
253 | (1) |
|
The Need for Clarity, Connection, and Goals |
|
|
254 | (1) |
|
How Distinctions Build a Culture Focused on the Future |
|
|
255 | (2) |
|
The First Important Distinction Is: Are You Playing to Win, or Are You Playing Not to Lose |
|
|
256 | (1) |
|
The Second Important Distinction Is: Do You Fall in Love With Your Patients, or Fall in Love With Your Product or Processes? |
|
|
256 | (1) |
|
|
|
257 | (1) |
|
The Value of Strategic Quitting |
|
|
257 | (1) |
|
How to Take the First Step and Maintain Momentum |
|
|
258 | (1) |
| Final discussion: Circular pharmaceutical care |
|
259 | (16) |
| List of abbreviations |
|
275 | (4) |
Appendix: Overview of Laws, Legislation, and Standards Referred to in
Chapter 17 |
|
279 | (14) |
| References |
|
293 | (14) |
| Index |
|
307 | |
